November 16, 2026 Global Pulse

Biosimilars Are Gaining Ground in Markets That Resisted Them

By Isabelle Fontaine | Senior Analyst, Cross-Sector Equity & Market Intelligence
8 min read

The biosimilar market has entered a phase of accelerating commercial penetration across therapeutic categories and geographies that had previously proven resistant to biologic reference product substitution, driven by the cumulative effect of payer coverage mandates, formulary exclusions of originator products, and mandatory biosimilar substitution policies that are overcoming the clinical inertia, patient advocacy resistance, and originator contracting strategies that slowed biosimilar adoption in the United States and several European markets relative to the market share trajectories that health economic modelling had projected when the first biosimilar approvals catalysed optimistic penetration forecasts a decade ago. The commercial significance of the adalimumab biosimilar market launch in the United States, where Humira's patent protection expired and multiple biosimilars including Hadlima, Hyrimoz, Cyltezo, and Yusimry entered the market from January 2023, represents the largest single biosimilar market event in pharmaceutical history given Humira's status as the world's highest-revenue drug with approximately $20 billion in annual US sales, and the commercial outcomes of this launch are providing data on US biosimilar market dynamics that will influence both originator and biosimilar manufacturer strategies for subsequent launches in oncology, haematology, and ophthalmology.

Adalimumab Biosimilars and the US Market Reality

The US adalimumab biosimilar market has demonstrated both the significant penetration potential and the structural complexities of biosimilar competition in the American payer system, where pharmacy benefit manager formulary decisions, rebate contracting, and patient assistance programmes interact to determine which products reach patients and at what net price. AbbVie's pre-emptive contracting strategy, which involved offering PBMs and payers substantial rebates on Humira in exchange for continued formulary exclusivity, succeeded in maintaining Humira on preferred formulary positions at several major PBMs through 2023 while biosimilars were offered at list price discounts that did not fully offset AbbVie's rebate offerings in net cost terms, limiting biosimilar penetration in the first year of market availability to levels well below the 50 to 70 percent substitution rates seen in European markets at equivalent stages of competition. Amgen's Amjevita, Samsung Bioepis's Hadlima partnered with Organon, Sandoz's Hyrimoz, and Coherus BioSciences's Yusimry are among the adalimumab biosimilars competing in a market where the PBM formulary landscape is gradually shifting as payers evaluate the total rebate economics of continued Humira exclusivity versus biosimilar inclusion, with Express Scripts and Cigna having made formulary decisions that are increasing biosimilar access and signalling a market share shift that will compound over the multi-year formulary cycle.

The interchangeability designation that the FDA has granted to several adalimumab biosimilars, which allows pharmacists to substitute the biosimilar for the prescribed originator without prescriber intervention in states with biosimilar substitution laws, is a commercially important regulatory status that removes a friction point in the substitution process, and the accumulation of post-market safety and efficacy data from biosimilar use at scale is progressively reducing the clinical hesitancy among rheumatologists and gastroenterologists that slowed adalimumab biosimilar adoption among their specialist prescriber populations.

Oncology Biosimilars and the Trastuzumab, Bevacizumab Markets

Oncology biosimilars for trastuzumab, bevacizumab, rituximab, and pertuzumab have achieved commercially significant market penetration in both European and US markets, with the institutional purchasing environment of hospital oncology departments and the involvement of pharmacy and therapeutics committees in formulary decisions creating adoption dynamics different from the retail and specialty pharmacy channels that govern autoimmune biosimilar access. Trastuzumab biosimilars from Mylan partnered with Biocon, Pfizer's Trazimera, Samsung Bioepis's Ontruzant, and Celltrion's Herzuma have collectively captured substantial share of the trastuzumab market in markets where group purchasing organisations and hospital formulary decisions have driven preferential biosimilar use in HER2-positive breast cancer and gastric cancer treatment protocols. The US oncology biosimilar market has been more commercially successful than the autoimmune biosimilar market due to the institutional purchasing dynamics that allow formulary substitution without the individual prescriber and patient consent hurdles that complicate retail pharmacy biosimilar substitution, and the oncology precedent is cited by biosimilar advocates as evidence that the US market can achieve meaningful biosimilar penetration when institutional purchasing structures align with payer coverage incentives.

Insulin and Biosimilar-Adjacent Markets

Insulin products, which occupy a regulatory classification adjacent to conventional biosimilars in the United States under the biologics pathway, have seen significant price competition following the introduction of authorised generic insulins and biosimilar insulins from Civica Rx, Amphastar Pharmaceuticals, and Viatris, with Eli Lilly, Novo Nordisk, and Sanofi having reduced list prices for their branded insulin products in response to political pressure and competitive dynamics that have materially changed the insulin affordability landscape for uninsured and underinsured patients who pay out-of-pocket. The commercial lessons from insulin price competition, where originator manufacturers chose aggressive list price reductions rather than ceding volume to biosimilar entrants, may inform originator strategies in future biosimilar competitions where the branded manufacturer's ability to retain market share through price concession is more commercially viable than the volume loss from formulary exclusion. The emerging biosimilar pipeline for newer biologic platforms including PD-1 inhibitors, IL-17 and IL-23 inhibitors, and VEGF inhibitors whose patents are approaching expiry represents the next phase of biosimilar market development, with biosimilars for pembrolizumab, secukinumab, and ixekizumab in clinical development and the commercial outcomes of their launches dependent on the regulatory, payer, and clinical adoption dynamics that the adalimumab and oncology biosimilar experience has begun to characterise. The global market for biosimilars is projected to exceed 100 billion dollars in annual sales by 2030 as additional reference biologic products lose exclusivity and payer mandates for biosimilar use expand across therapeutic categories from immunology and oncology into endocrinology and haematology where biologic therapies have become standard of care.

Top 10 Companies in Biosimilars and Biologics Market Access

  1. Samsung Bioepis -- Korean biosimilar developer with one of the largest approved biosimilar portfolios including adalimumab, etanercept, trastuzumab, and bevacizumab biosimilars, partnering with Organon and Biogen for US and European commercialisation of its approved products.
  2. Celltrion -- Korean biosimilar manufacturer with integrated manufacturing and commercial operations, marketing infliximab, trastuzumab, and rituximab biosimilars including Remsima and Herzuma through its own sales infrastructure in key markets.
  3. Sandoz (Novartis) -- Global biosimilar leader being spun off from Novartis with one of the broadest approved biosimilar portfolios across filgrastim, adalimumab, etanercept, and rituximab, with established European and growing US commercial biosimilar operations.
  4. Amgen -- US biopharmaceutical company with significant biosimilar business including Amjevita adalimumab, Mvasi bevacizumab, and Kanjinti trastuzumab, leveraging its biologics manufacturing expertise to compete in biosimilar markets alongside its branded product portfolio.
  5. Biocon Biologics -- Indian biopharmaceutical company with global biosimilar portfolio in insulin, trastuzumab, bevacizumab, and adalimumab, partnering with Viatris for commercialisation and operating its own manufacturing at scale in Bangalore for global supply.
  6. Pfizer (Biosimilars) -- US pharmaceutical giant with significant biosimilar commercial presence through Inflectra infliximab, Trazimera trastuzumab, and Zirabev bevacizumab, applying its hospital oncology and specialty sales infrastructure to drive biosimilar adoption in institutional purchasing channels.
  7. Coherus BioSciences -- US biosimilar company with FDA-approved adalimumab biosimilar Yusimry and trastuzumab biosimilar Trazimera partnership, targeting the US autoimmune and oncology biosimilar markets with a focused commercial strategy.
  8. Formycon -- German biosimilar developer with ranibizumab and ustekinumab biosimilar pipeline, partnering with larger pharmaceutical companies for commercialisation while maintaining biosimilar development expertise in ophthalmology and immunology indications.
  9. Civica Rx -- US non-profit generic and biosimilar medicine company working to provide affordable insulin and essential medicines, with insulin biosimilar development targeting price reduction for uninsured and Medicare Part D patients facing out-of-pocket insulin costs.
  10. Fresenius Kabi -- German healthcare company with biosimilar portfolio including adalimumab, trastuzumab, and bevacizumab biosimilars marketed in the US and Europe, leveraging its hospital pharmacy relationships and injectable drug manufacturing capabilities in the biosimilar market.

Our Take

The biosimilar market is past the point where adoption uncertainty is the dominant commercial question, as the adalimumab launch in the US and the established European markets have demonstrated that payer-driven formulary decisions can generate meaningful biosimilar penetration even in the face of originator contracting strategies that were specifically designed to prevent it. The more commercially interesting questions now concern the pace at which the US market converges toward European penetration levels, which products in the next wave of biosimilar launches will achieve the institutional purchasing traction that oncology biosimilars demonstrated, and whether the interchangeability designation pathway will meaningfully change retail pharmacy substitution dynamics for autoimmune biosimilars where individual prescriber and patient consent has been the adoption friction point. For biosimilar manufacturers, the competitive dynamics are intensifying as multiple high-quality manufacturers compete on price in markets where the manufacturing quality differentiation that justified premium biosimilar pricing is increasingly assumed rather than rewarded, and the commercial success in biosimilars will increasingly depend on commercial excellence, payer relationship management, and manufacturing cost competitiveness rather than the development and regulatory execution that characterised the first generation of biosimilar competition. -- Daniel Osei, MarketsNXT

Back to All Insights
×